SCHEMBL2835301

SCHEMBL2835301

COc1cc(C)c(S(=O)(=O)N2CCCCC2COc2ccnc(N3CCC(Oc4ccccn4)CC3)n2)c(C)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP3 P42574 4/20 0.38
SCN9A Q15858 1/20 0.37
GPR119 Q8TDV5 1/20 0.36
NAAA Q02083 2/20 0.36
PDE3B Q13370 1/20 0.35
PDE3A Q14432 1/20 0.35
PDE10A Q9Y233 1/20 0.35
RET P07949 3/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35
HSD17B10 Q99714 1/20 0.35
CASP7 P55210 3/20 0.34
CHRM4 P08173 1/20 0.34
ADORA2A P29274 2/20 0.33
ADORA1 P30542 2/20 0.33
ACACB O00763 1/20 0.33
CASP1 P29466 1/20 0.33
CASP2 P42575 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2836402 0.90 NAAA (0.46) CASP3GPR119NAAACASP7CASP1
SCHEMBL2836786 0.90 KMT2A (0.39) CASP3KDM4EALDH1A1LMNAMAPT
SCHEMBL2830570 0.87 KDM4E (0.39) CASP3NAAAPDE3BPDE3APDE10A
SCHEMBL2832996 0.87 KMT2A (0.40) CASP3KDM4EALDH1A1LMNAMAPT
SCHEMBL2836548 0.86 CA12 (0.38) CASP3KDM4EALDH1A1HSD17B10CASP7
SCHEMBL2832792 0.85 PDE10A (0.36) CASP3PDE10AKDM4EALDH1A1LMNA
SCHEMBL2835907 0.84 ALDH1A1 (0.38) CASP3KDM4EALDH1A1LMNAMAPT
SCHEMBL2839870 0.84 HTR7 (0.38) CASP3KDM4EALDH1A1CASP7CHRM4
SCHEMBL2836146 0.84 CASP3 (0.39) CASP3KDM4EALDH1A1MAPTCASP7
SCHEMBL2832782 0.83 CA12 (0.39) CASP3ALDH1A1CASP7CASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2356101-B1 PYRIMIDINE- AND TRIAZINE-SULFONAMIDE DERIVATIVES AS BRADYKININ B1 RECEPTOR (B1R) INHIBITORS FOR THE TREATMENT OF PAIN GRUENENTHAL GMBH (DE) 2013-02-27 EP claimed
US-8269000-B2 Substituted pyrimidine and triazine compounds GRUENENTHAL GMBH (DE) 2012-09-18 US claimed
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds GRUENENTHAL GMBH (DE) 2010-07-08 US claimed
US-8269000-B2 Substituted pyrimidine and triazine compounds GRUENENTHAL GMBH (DE) 2012-09-18 US disclosed
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds GRUENENTHAL GMBH (DE) 2010-07-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds ADORA2B, CCNB1, TYMS CASP3 1252/4885SCN9A 402/4885GPR119 893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.